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CD8+ cytotoxic T lymphocytes (CTL) play an important role in controlling virus replication in HIV- and SIV-infected humans and monkeys,
respectively. Three well-studied SIV CTL determinants are the two Mamu A⁎01-restricted epitopes Gag CM9 and Tat SL8, and the Mamu B⁎17-
restricted epitope Nef IW9. Point mutations leading to amino acid replacements in these epitopes have been reported to mediate SIV escape from
CTL control. We found that synthetic peptides containing mutations in SIV Gag CM9 and Tat SL8 were no longer recognized by the respective
CTL. On the other hand, the described I-to-T replacement at the N-terminal amino acid residue of the SIV Nef IW9 epitope only moderately
affected CTL recognition of the variant peptide, TW9. In an attempt to dissect the mechanism of escape of the Nef TW9 mutation, we investigated
the effect of this mutation on CTL recognition of CD4+T cells infected with an engineered SIVmac239 that contained the TW9 mutation in Nef.
Although, the wild type and mutant virus both infected and efficiently replicated in rhesus macaque CD4+T cells, the TW9 mutant virus failed to
induce IFN-γ expression in an SIV Nef IW9-specific CTL clone. Thus, unlike escape from Gag CM9- or Tat SL8-specfic CTL control presumably
by loss of epitope binding, these results point to a defect at the level of processing and/or presentation of the variant TW9 epitope with resultant
loss of triggering of the cognate TCR on CTL generated against the wild type peptide. Our data highlight the value of functional assays using
virus-infected target cells as opposed to peptide-pulsed APC when assessing relevant escape mutations in CTL epitopes.
Published by Elsevier Inc.Keywords: AIDS; CD8+T-cell clones; Immune escape; Nef; SIVIntroduction
Although virus-specific CTL can control HIV or SIV repli-
cation in infected humans and monkeys, respectively, (Allen
et al., 2002; Barouch et al., 2001; Borrow et al., 1994; Egan
et al., 2000; Froebel et al., 1994; Gruters et al., 2002; Kuroda
et al., 1999; Rowland-Jones et al., 2001) the virus eventually
overwhelms the immune system. Mutations in immunodomi-
nant CTL epitopes have been reported to mediate viral escape
from CTL control (Allen et al., 2004, 2000a,b; Barouch et al.,
2002; Borrow et al., 1997; Goulder et al., 2001; Johnson and
Desrosiers, 2002b; Leslie et al., 2004; O'Connor et al., 2002).⁎ Corresponding author. AIDS and Cancer Virus Program, SAIC-Frederick,
Inc., NCI-Frederick, P.O. Box B, Frederick, MD 21702, USA. Fax: +1 301 846
5588.
E-mail address: cohlen@ncifcrf.gov (C. Ohlen).
0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2008.02.005These mutations could prevent either peptide binding to
restricting MHC class I molecules or peptide–MHC class I-
complex recognition by the cognate TCR. Alternatively,
mutations can also affect proteolytic processing required to
generate epitope peptides, leading to loss of presentation
(Milicic et al., 2005). These escape mutations pose a major
challenge in the development of putative HIV-1 vaccines aimed
at inducing virus-specific CTL responses, hence, the role of
different mutations within major HIV or SIV CTL epitopes in
immune escape is the subject of intense investigation (Allen et
al., 2004,2000a,b; Barouch et al., 2002, Borrow et al., 1997;
Goulder et al., 2001; Johnson and Desrosiers, 2002b; Leslie et
al., 2004; O'Connor et al., 2002). However, the oligoclonality
of the CTL response to the virus in vivo and the possibility that
CTL responses can co-evolve with viral escape variants in
infected individuals has complicated this effort (Haas et al.,
1996).
Table 1
Intracellular cytokine responses to wild type and variant peptides
SIV CTL epitope Peptide sequencec % IFN-γ producing cellsd
Gag CM9a CTPYDINQM (wild type) 85.2
CAPYDINQM (T2A) 0.1
CSPYDINQM (T2S) 4.1
Tat SL8a STPESANL (wild type) 75.4
PTPESANL (S1P) 1.4
Nef IW9b IRYPKTFGW (wild type) 37.7
TRYPKTFGW (I1T) 39.2
Analyses by ICS and flow cytometry.
aMamu A⁎01-restricted epitope.
bMamu B⁎17-restricted epitope.
cWild type peptide sequence and observed mutations in CTL epitopes in virus
isolated from a chronically infected rhesus macaque.
dFrequency of cells positive for IFN-γ in clonal population of CTL generated
against WT peptide after stimulation with APC pulsed with 5 μg/mL of WT or
variant peptide.
Fig. 1. WT Nef IW9 and the variant Nef TW9 peptide elicit IFN-γ production in
Nef IW9-specifc CTL. Herpesvirus papio-transformed B-cells or CD4+T cells
pulsedwith 10-fold serial dilutions of the IRYPKTFGW(IW9) or TRYPKTFGW
(TW9) peptide (5 μg/mL down to 1 pg/mL) were used as APC to stimulate
autologous SIV Nef IW9-specific CTL generated from an SIVmac239-infected
rhesus macaque in a 5 h assay. The frequency of IFN-γ expressing CD8+T cells
was determined by flow cytometry. Shown are the means and SD at different
peptide concentrations for three independent experiments.
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eliciting CTL responses to one or a combination of the early
expressed viral accessory proteins Tat and Nef, and the late ex-
pressed structural protein Gag (Amara et al., 2001; Barouch et al.,
2002; Gallimore et al., 1995). Immunodominant epitopes within
each of these proteins have been described, the most widely
reported being the Mamu A⁎01-restricted SIV Gag181–189CM9
(CTPYDINQM, Gag CM9) and Tat28–35SL8 (STPESANL, Tat
SL8) epitopes, and the Mamu B⁎17-restricted Nef165–173IW9
(IRYPKTFGW, Nef IW9) epitope (Allen et al., 2000b; Friedrich
et al., 2004c; Loffredo et al., 2007; O'Connor et al., 2003). Mu-
tations have been reported to occur within the Tat SL8 epitope
very early (3–4weeks) during acute infection (Allen et al., 2000b;
Borrow et al., 1997; O'Connor et al., 2002) while mutations in the
Gag CM9 epitope tend to occur much later (N12 months) during
chronic infection (Barouch et al., 2002; O'Connor et al., 2002).
This difference is apparently due to the negative impact of
mutations within the Gag CM9 epitope on the replicative fitness
of the virus with resultant extraepitopic compensatory mutations
necessary for viral persistence in vivo (Friedrich et al., 2004a,b).
Nef-specific CTL activity is thought to be an important
component of the cell-mediated immune response necessary to
control viral replication and spread (Gallimore et al., 1995).
Besides its central role in promoting efficient viral replication
(Johnson and Desrosiers, 2002a), Nef displays immunoregula-
tory properties such as downregulation of CD4 and MHC class I
expression on virally-infected cells (Bell et al., 1998; Hrecka
et al., 2005; Mangasarian et al., 1999; Piguet et al., 1999;
Schwartz et al., 1996; Venzke et al., 2006), the latter protecting
virally-infected cells from MHC class I-restricted T-cell re-
cognition. A substitution of an isoleucine (IW9) with a threonine
(TW9) residue at the N-terminus (p1) of the immunodominant
SIV Nef IW9 epitope has been described (Friedrich et al.,
2004c). Unlike the mutations in the Gag CM9 epitope, there is
very limited information on the impact of the Nef TW9mutation
on viral replicative fitness (Friedrich et al., 2004c; O'Connor
et al., 2002). Furthermore, the mechanism of escape of SIV Nef
TW9 mutant virus from SIV Nef IW9-specific CTL recognition
is not known.In this study, we investigated the mechanisms behind CTL
escape in three well-studied immunodominant SIV epitopes.
Using WT and variant synthetic peptides corresponding to the
SIV Gag CM9, Tat SL8 and Nef IW9 epitopes and a mutant Nef
TW9 virus, we show that while mutations within the Gag CM9
and the Tat SL8 epitopes abrogate binding to MHC class I and/
or cognate TCR, the SIV Nef TW9 mutation abrogates CTL
recognition by interfering with processing and/or presentation
without negatively impacting viral replicative capacity.
Results
Mutant SIV Gag CM9 and Tat SL8 peptides are not recognized
by SIV-specific CTL clones while mutant Nef IW9 peptide
induces similar levels of IFN-γ expression as the WT peptide
The SIVGagCM9T2Aor T2S, Tat SL8 S1P andNef IW9 I1T
(TW9) epitope mutations have been reported to occur in vivo in
SIV-infected Mamu A⁎01/B⁎17 positive rhesus macaques
(Barouch et al., 2002; Friedrich et al., 2004a,b,c; O'Connor
et al., 2002). To test the potential cross-reactivity between theWT
and variant peptides, we compared induction of IFN-γ expression
in SIV Gag CM9-, Tat SL8-, or Nef IW9-specific CTL clones
following co-culture with an autologous B-cell line pulsed with
either SIV WT or the variant peptides.
The SIV Gag CM9 T2A and Tat SL8 S1P mutations did not
induce a measurable response at 5 μg/mL (saturating peptide
concentration) whereas the WT peptides produced strong re-
sponses (85.2% and 75.4% for Gag CM9 and Tat SL8, re-
spectively) (Table 1).The Gag CM9 T2S variant peptide
induced IFN-γ in only a small fraction (b5%) of the Gag
CM9-specific CTL at the highest peptide concentration tested.
This suggests that these mutations interfere with binding of the
peptide to either the restricting MHC class I molecule or to the
cognate T-cell receptor. In contrast, the variant Nef TW9 peptide
induced IFN-γ expression in a Nef IW9-specific CTL clone at
Fig. 2. Schematic representation of Nef gene sequence present in infectious molecular clone of SIVmac239. Nef reading frame begins at nucleotide 9348 and ends at
10,139 (numbering of Regier and Desrosiers, 1990). AT to C point mutation was introduced at position 9841 in the downstream 3' region (9840–9866) encoding the
Mamu B⁎17-restricted SIV Nef IW9 epitope leading to an isoleucine to threonine switch at position 1 of the 9-mer Nef CTL epitope.
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expression was evaluated against titrated amounts of the WT
Nef IW9 or variant TW9 peptide in repeated experiments, the
two peptides showed similar titration curves for IFN-γ in-
duction in an SIV Nef IW9-specific CTL with a moderately
lower frequency of cells responding to the variant peptide
(Fig. 1). Hence, both the WT Nef IW9 and variant TW9 pep-
tides can efficiently induce cytokine expression in a CTL clone
generated against the WT peptide, demonstrating that the va-
riant TW9 peptide can bind the restricting MHC class I allele
and the resulting complex can bind and trigger the cognate TCR
of the WT IW9-specific CTL. We also observed that polyclonal
CTL lines generated against the variant TW9-peptide showed a
similar degree of cross-reactivity to WT IW9-peptide-pulsed
APC (data not shown), further showing a comparable ability of
the TW9 peptide to bind both the restricting MHC class I
molecule and the cognate TCR.Fig. 3. Mutant SIVmac239 Nef TW9 infects and replicates in rhesus macaque CD4
+T
cells from a rhesus macaque infected with WT SIVmac239 (Nef IW9) or the mutant
1×106 cells/mL. The frequency of SIV Gag p27 expressing CD4+T cells was determSIV Nef TW9 mutant virus retains its full capacity to infect and
replicate in rhesus macaque CD4+T cells but does not
stimulate a Nef IW9-specific CTL clone
Given our finding that the WT Nef IW9-specific CTL can
recognize APC pulsed with a Nef TW9 variant peptide, we next
wanted to characterize a virus that expressed the Nef TW9
mutation in terms of infectivity, replicative capacity and recog-
nition of mutant virus-infected cells by WT Nef IW9-specific
CTL. To this end we engineered an SIVmac239 (Kestler et al.,
1990) variant virus with the described I-to-T replacement at p1
of the Nef IW9 epitope (Fig. 2) and then infected rhesus
macaque CD4+T cells with either the WT or mutant virus. Viral
infectivity, replication and spread were analyzed by PCR/RT-
PCR and flow cytometry.
Rhesus macaque CD4+T cells were effectively infected by
the mutant SIV Nef TW9 virus (Fig. 3). The kinetics of viralcells at levels comparable with WT SIVmac239 Nef IW9 virus in vitro. CD4
+T
Nef TW9 virus were cultured in 24-well tissue culture plates at a cell density of
ined at 24, 72, 120 and 168 h post infection by flow cytometry.
Table 2
Quantification of virus
Treatment a Proviral DNAb Viral RNAc
Uninfected cells d≤6.7×102 d≤1.5×103
Nef IW9 infected cells 1.5×108 5.4×109
Nef TW9 infected cells 2.2×108 5.5×109
a Rhesus macaque CD4+T-cell clone, uninfected, infected with wild type
SIVmac239 Nef IW9 or mutant Nef TW9.
b DNA copies/100,000 cells determined by QPCR.
c RNA copies Eq/mL cell culture supernatants determined by RT-PCR.
Analyses performed on day 8 post infection.
d Assay sensitivity threshold.
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the highest frequency of SIV Gag p27 positive CD4+T cells
seen around day 8 PI (Fig. 3). In the absence of addition of more
target cells, a massive loss of CD4+T cells was observed in
cultures of both the WT and mutant virus-infected cells beyond
day 8 PI (data not shown). Similar levels of proviral DNA and
viral RNA copies were observed in cultures of CD4+T cells
infected with the WT or mutant virus on day 8 PI (Table 2).
Thus, the IW9 to TW9 switch in the immunodominant SIV Nef
epitope did not have any observable effects on the virus in-
fectivity and/or replication.
Having demonstrated similar infectivity and replicative ca-
pacity of WT and mutant SIV Nef TW9 virus, we next in-
vestigated if the SIV-specific CTL clone generated against WT
Nef IW9 peptide recognized CD4+T cells infected with the
mutant SIV Nef TW9 virus. Rhesus macaque CD4+T cells
infected with WT SIV Nef IW9 or mutant Nef TW9 virus were
used as APC to stimulate an autologous SIV Nef IW9-specific
CTL clone, and IFN-γ production by the virus-specific CTL
assessed by flow cytometry.
Although the frequency of SIV Gag p27 positive CD4+T
cells infected with the WT Nef IW9 or mutant Nef TW9 virusFig. 4. Rhesus macaque CD4+T cells infected with the mutant SIVmac239 Nef TW9
clone. CD4+T cells infected with either WT SIVmac239 (Nef IW9) or the mutant Nef
CTL clone at a CD8+:CD4+T cell ratio of 1:1. To allow for optimal numbers of infecte
frequency of IFN-γ-expressing CTL was determined by flow cytometry. An autologwere similar in the day 8 PI cultures, only the WT Nef IW9-
infected CD4+T cells elicited intracellular IFN-γ expression in
the SIV Nef IW9-specific CTL clone (Fig. 4). Hence, the CTL
were capable of recognizing the mutant peptide sequence when
presented as a preformed synthetic peptide, while the point
mutation abrogated recognition of infected cells. An SIV Gag
CM9-specific CTL clone responded to both the WT Nef IW9
and mutant Nef TW9 virus-infected CD4+T cells.
Discussion
We have tested the effect on T-cell triggering by different
reported SIV escape mutations using synthetic peptides cor-
responding to variant amino acid sequences and an engineered
SIV mutant virus. Two different independent mutations in SIV
Gag CM9 and one in Tat SL8 resulted in an almost complete
loss of T-cell triggering, demonstrating that these mutations
impede peptide binding to either the MHC class I molecule or to
the cognate TCR. In contrast, the I1T substitution in the SIV Nef
IW9 CTL epitope only moderately affected CTL recognition as
analyzed using peptide-pulsed APC. Further analysis of the
effect of the SIV Nef TW9mutation on viral replicative capacity
using an engineered SIV Nef TW9 mutant virus showed that
this single amino acid substitution had no discernible negative
impact on viral replicative capacity. However, the I1T change
was sufficient to abrogate recognition of SIV-infected cells by
CTL generated against the WT SIV Nef IW9 sequence.
The efficient induction of intracellular IFN-γ expression in
the CTL clone generated against the WT SIV Nef IW9 peptide
by the variant SIV Nef TW9 peptide-pulsed APC suggests a
preserved capacity of the variant peptide to bind the MHC class
I molecule and effectively trigger the cognate T-cell receptor.
This confirms and extends results of an in vivo study (Fried-
rich et al., 2004c) showing that Nef IW9-specific CTL linesvirus fail to elicit IFN-γ production in a WT SIV Nef IW9-specific CD8+T-cell
TW9 virus were used as APC to stimulate an autologous SIV Nef IW9-specific
d target cells, day 8 post infection CD4+T cells were used as stimulator cells. The
ous SIV Gag CM9-specific CTL clone was included as a positive control.
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altered sequences of the immunodominant peptide. In addition,
the same group recently showed, using ELISpot, similar bind-
ing avidities of Nef IW9-specific CTL lines for WT and p1
variant peptides (I1A or I1T) but not peptide with concurrent
variations at p1 and p6 (I1T+ I6 M) (Valentine et al., 2007).
While the latter study involved IW9-specific CTL lines, the data
together with our own current findings, suggest that the single
amino acid change at p1 in the Nef IW9-epitope only mode-
rately affects the binding avidity of the variant peptide to the
MHC class I molecule or the cognate TCR. Thus, we reasoned
that this single amino acid substitution mainly affects intra-
cellular events occurring prior to MHC class I binding and
subsequent interaction with the specific CTL.
To investigate the effect of the SIV Nef TW9 mutation on
antigen processing and presentation in physiologically relevant
SIV-infected autologous CD4+T cells rather than using trans-
formed B-cell targets pulsed with synthetic peptides, we made a
mutant virus expressing the Nef TW9 mutation and used in-
fected CD4+Tcells as APC. Given reports of a fitness cost to the
virus in vivo following mutations in immunodominant CTL
epitopes in other SIV proteins such as Gag (Friedrich et al.,
2004a,b,c), we assessed the replicative capacity of the engi-
neered SIV Nef TW9 mutant virus in autologous CD4+T cells
prior to use as APC in vitro. We show here that the single amino
acid replacement at the N-terminus of the immunodominant
SIV Nef IW9 CTL epitope does not adversely affect the ability
of the virus to infect and replicate in primary rhesus macaque
CD4+T cells. However, a very low number (b3%) of Nef IW9-
specific CTL responded with IFN-γ production after exposure
to cells infected with the mutant virus compared with WT virus.
These data are in agreement with both an earlier study which
showed that monkeys infected with an SIV mutant Nef virus did
not generate a CTL response against the Nef IW9 WT epitope
(Friedrich et al., 2004c), as well as with a recent paper by
Valentine et al. showing that cells infected with the Nef TW9
mutant virus were very poor APC for IW9-specific polyclonal
T-cell populations (Valentine et al., 2007). Together with the
data using peptide-pulsed APC for CTL stimulation, these
results point to a defect in the ability of SIV Nef TW9 mutant
virus-infected cells to correctly generate and/or process the
relevant epitope, rather than impaired binding to MHC class I or
the TCR of the Nef IW9 specific T cells. It can not be ruled out,
however, that the mutant TW9 peptide binds either the MHC or
the TCR with slightly lower affinity, as indicated by the peptide
titration. This could lead to a scenario where infected cells
presenting low amounts of peptide would suboptimally present
the TW9 epitope, leading to a lack of CTL activation. Alter-
natively, the variant TW9 epitope could be generated in virally-
infected cells but at a lower efficiency with lower concentrations
eventually being presented on the cell surface, leading to loss of
TCR triggering. Regardless, the precise step/mechanism of the
processing/presentation defect remains a subject worth inves-
tigating further. Bauer et al. (1997) reported that structural
constraints of HIV-1 Nef may curtail escape from HLA-B7-
restricted CTL recognition. Our data showing lack of CTL
recognition of mutant SIV Nef TW9-infected target cells, de-spite efficient recognition by the same CTL of APC pulsed with
the variant TW9 peptide, suggest that such structural con-
strains do not apply for SIV Nef IW9 escape from Mamu B⁎17-
restricted CTL.
Taken together, our data demonstrate that the I-to-T re-
placement at the N-terminal amino acid residue of the immu-
nodominant SIV Nef IW9 epitope does not negatively impact
viral replicative capacity but causes defective processing and/or
presentation of the variant peptide with resultant loss of infected-
cell recognition by the WT SIV Nef IW9-specific CTL. The abi-
lity to differentiate mutations that interfere directly with binding
required for antigen–MHC class I-complex formation and inter-
action with cognate TCR (e.g. SIVGag CM9 T2A or T2S and Tat
SL8 S1P) from those that prevent antigen processing and/or
presentation (e.g. SIV Nef IW9 I1T) is an important tool for
analyzing viral escape mutants. This highlights the importance of
including functional assays using virus-infected target cells (Tsu-
bota et al., 1989; Yang, 2003) as opposed to assays using peptide-
pulsed APC in assessing CTL escape mutations.
Materials and methods
Generation of SIV Gag181–189CM9-, Tat28–35SL8- and
Nef165–173IW9-specific CD8
+ and autologous CD4+T-cell clones
SIVGag181–189CM9 (CTPYDINQM,GagCM9)-, Tat28–35SL8
(STPESANL, Tat SL8)- and Nef165–173IW9 (IRYPKTFGW, Nef
IW9)-specific CTL clones were isolated from a Mamu A⁎01
and B⁎17 double positive Indian rhesus macaque, Macaca
mulatta, chronically infected with SIVmac239, as described
previously (Andersen et al., 2007). Viral sequencing showed
that in the chronic phase of infection the circulating plasma
virus in this monkey contained the following mutations in the
three immunodominant CTL epitopes; SIV Gag CM9 T2A and
T2S, Tat SL8 S1P and Nef IW9 I1T (TW9) (Table 1 and
unpublished data). PBMC from the monkey were stimulated
for 1 week with irradiated autologous PBMC pulsed with CM9,
SL8 or IW9 peptide (all from SynPep Corp., Dublin, CA). The
cultures were restimulated weekly with CM9, SL8 or IW9
peptide-pulsed and irradiated autologous PBMC in the pre-
sence of recombinant human IL-2 (50 IU/mL: NIH AIDS
Research and Reference Reagent Program, Germantown, MD).
Following 2 rounds of stimulation, the CM9-, SL8- or IW9-
specific CTL were cloned by limiting dilution and maintained
essentially as described by Riddell and Greenberg (1990) and
Berger et al. (2001), using bi-weekly anti-CD3 monoclonal
antibody (mAb) (30 ng/mL; clone SP34-2; BD Biosciences,
San Diego, CA, USA) stimulation with irradiated human
PBMC and human Epstein Barr virus-transformed B-cells (TM
B-LCL; kindly provided by Drs. S.R. Riddell and P.D.
Greenberg, FHCRC, Seattle, WA) as feeder cells, but without
anti-CD28 mAb stimulation. APC and feeder cells were ir-
radiated in a Mark I Cs137 γ-irradiator (Shepherd & Associates,
San Fernando, CA) at 6000 and 12,500 rad for PBMC and TM
B-LCL, respectively. Positive wells were tested for antigen
specificity by flow cytometry using ICS for IFN-γ production
following stimulation with cognate peptide-pulsed APC and by
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IW9 (both from NIH AIDS Research and Reference Reagent
Program) peptide/MHC-tetramers.
Autologous CD4+T-cell clones were generated as described
(Andersen et al., 2007). Briefly, highly enriched CD4+T cells
were isolated from PBMC or splenocytes by negative selection
using Miltenyi LD columns and anti-CD8 microbeads followed
by positive selection using MS columns and anti-CD4 microbe-
ads (Miltenyi Biotec Inc., Auburn, CA). CD4+T-cell clones
were obtained after 2-weeks expansion in limiting dilution
cultures containing irradiated human PBMC, IL-2 and anti-CD3
mAb and maintained as described above for CTL clones. In
contrast to the CD8+T-cell clones, the CD4+T-cell clones did
not have a defined antigenic specificity.
Virus stocks
The SIV isolate used in this study was derived from the
molecular clone SIVmac239 (Genbank accession no. M33262.1)
(Kestler et al., 1990). SIVmac239 Nef TW9 was generated by
introducing a T to C point mutation at position 9841 in the
downstream 3' region (9840–9866) encoding the Mamu B⁎17
restricted SIV Nef IW9 epitope leading to an isoleucine to
threonine substitution at p1 of the 9-mer Nef CTL epitope. SIV
virus stocks were produced by transfection of HEK293T cells
with the wild type (Nef IW9) or mutant (Nef TW9) SIVmac239
using TransIt 293 reagent (Mirus Corp., Madison, WI) ac-
cording to the manufacturer's recommendations. HEK293T
cells were maintained in high glucose or Dulbecco modified
Eagle medium (DMEM) supplemented with 10% heat-inacti-
vated fetal calf serum, 2 mM L-glutamine, 50 U of penicillin per
mL and 50 μg of streptomycin per mL (Invitrogen Corp.,
Carlsbad, CA, USA). Viral RNA content was determined as
detailed below (see ‘Viral load analysis’).
Infection of a CD4+T-cell clone with SIVmac239 Nef IW9 or Nef
TW9
A clonal population of resting CD4+Tcells was activated with
anti-CD3mAb (T-25 flask-bound: 5 µg/mL) and IL-2 (50 IU/mL)
for 48 h and then incubated with aliquots of freshly prepared virus
stocks using the Viromag magnetofection reagents and proce-
dures according to manufacturer's recommendation (OzBios-
ciences, Marseille, France). Approximately 0.25 mL virus stock
containing 1.2×109 viral RNA copies Eq/mL were added per
1×106 CD4+T cells. Incubations were carried out on a magnetic
plate at 37 °C in a humidified atmosphere of 5% CO2 for 2 h and
the virus-exposed CD4+Tcells washed twice with PBS to remove
residual non-incorporated viral material prior to use in assays.
Enumeration of virus-infected CD4+T cells by intracellular
staining for SIV Gag p27
Staining for surface markers (CD3 and CD4) and intracellular
SIV Gag p27 was performed to assess the levels of SIV infection
at different time points post infection (PI). All antibodies were
obtained from BD Biosciences (San Diego, CA, USA) unlessotherwise indicated. Cells were washed once in FACS surface
buffer (PBS, 1% rat sera, 1% mouse sera, 0.05% sodium azide)
and mAbs to the following surface markers conjugated to the
indicated fluorochromes were added: CD4-PE or PerCP-Cy5.5
(cloneL200) andCD3-APC (clone SP34-2). Cells were incubated
for 30 min at 4 °C, washed with sterile PBS and then fixed with
4% paraformaldehyde (PFA), 500 μL/sample tube for 30 min at
4 °C. The cells were permeabilized (PBS, 0.1% saponin, 1% rat
sera, 1%mouse sera and 0.05% sodium azide), 1 mL/sample tube
for 5 min, washed (0.1% saponin in PBS) and incubated with
FITC conjugated anti-SIV Gag p27 mAb (Clone 55-2F12, NIH
AIDS Research and Reference Reagent Program). A final wash
was performed and the cells resuspended in 0.1% PFA. Samples
were acquired on a BD FACSCalibur flow cytometer (BD Bio-
science) and subsequent data analyses performed using FCS
Express Version 3 (De Novo Software, Thornhill, Ontario, Ca-
nada). Dead cells were excluded from the analyses based on
forward versus side scatter gating, and at least 100,000 live cell
events collected for each sample.
Measurement of IFN-γ expression by SIV-specific CTL clones
in response to peptide-pulsed or SIV-infected target cells
SIV-specific CTL clones were co-cultured with autologous
herpesvirus papio-transformed B-cell lines pulsed with dilu-
tions of peptides in 5 mL polypropylene tubes. Alternatively,
CD4+T cells infected with WT Nef IW9 or mutant Nef TW9
virus were used as APC to stimulate the autologous SIV Nef
IW9-specific CTL clone. The virus-infected CD4+T cells had
been in culture for 7 or 8 days prior to use as APC; in our
system, the incubation period needed to achieve peak fre-
quencies of SIV Gag p27 expressing target cells (Minang et al.,
in press). A CTL:target cell ratio of 1:1 with a total of 1×106
cells in a final volume of 2 ml per tube was used and non-pulsed
autologous B-cells or uninfected autologous CD4+T cells were
used as negative control APC. Monensin, 20 μL/test of a 1:20
dilution, (Golgi stop™; BD Bioscience) was added after an
hour of incubation and the cultures incubated for additional 4 h.
Cells were washed, surface and intracellular stained, as
described above, with PerCP-Cy5.5 conjugated anti-human
CD8 mAb (clone SK1) and FITC conjugated anti-human IFN-γ
mAb (clone 4S.B3), respectively. Samples were acquired and
analyzed as described above.
Viral load analysis
Viral RNAwas extracted from culture supernatant essentially
as described previously (Cline et al., 2005) and viral replication
quantified using FRET probe-based real time RT-PCR (TaqMan)
as described (Cline et al., 2005; Lifson et al., 2001). All PCR
reactions were run on ABI Prism 7700 Sequence Detection Sys-
tem and the fluorescent signal-based quantitation of viral RNA
copy numbers in test samples were determined by ABI sequence
detection software (Applied Biosystems, Foster City, CA).
Cell-associated DNA was extracted using the Qiagen DNA
MiniKit as recommended by themanufacturer (Qiagen, Valencia,
CA, USA). The copy numbers of SIV DNA (gag-specific target)
313J.T. Minang et al. / Virology 375 (2008) 307–314and that of the gene sequence for macaque CCR5, as reference for
cell equivalents, were co-determined in a duplex format QPCR as
described by Cline et al. (2005) with omission of the reverse
transcription step, and with the addition of primers (100 nM final
concentration, each) and probe (100 nM final concentration)
specific for the macaque CCR5 sequence and use of a cloned
genomic fragment of the rhesus macaque CCR5 gene as standard
(Genbank Acc. No. AF252567) (the Plasmid pR1-D, of the Ma-
cacamulattaCCR5 gene, promoter regionwas a kind donation of
Dr. Sunil K. Ahuja of the University of Texas Health Science
Center SanAntonio, SanAntonio, Texas) (Mummidi et al., 2000).
The duplex QPCR assay was run on an MX3000P™ instrument
(Stratagene, La Jolla, CA) and results are reported as nominal SIV
gag DNA copy numbers per 10,000 cell equivalents determined
by copy numbers of the CCR5 sequence and based on 2 nominal
copies of CCR5 per rhesus macaque cell (M. Piatak, unpublished
results).
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